Scientists grow perfect human blood vessels in a petri dish

Medical Xpress | January 16, 2019

Scientists have managed to grow perfect human blood vessels as organoids in a petri dish for the first time. The breakthrough engineering technology, outlined in a new study published today in Nature, dramatically advances research of vascular diseases like diabetes, identifying a key pathway to potentially prevent changes to blood vessels—a major cause of death and morbidity among those with diabetes. An organoid is a three-dimensional structure grown from stem cells that mimic an organ and can be used to study aspects of that organ in a petri dish. "Being able to build human blood vessels as organoids from stem cells is a game changer," said the study's senior author Josef Penninger, the Canada 150 Research Chair in Functional Genetics, director of the Life Sciences Institute at UBC and founding director of the Institute for Molecular Biotechnology of the Austrian Academy of Sciences (IMBA).

Spotlight

Climate scientists warn that 2019 may be the warmest year on record largely as the result of a possible El Niño event exacerbated.

Spotlight

Climate scientists warn that 2019 may be the warmest year on record largely as the result of a possible El Niño event exacerbated.

Related News

MEDICAL

Absci Opens Door to New Biotechnology Campus

Absci | October 23, 2021

Absci Corporation the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the opening of its new campus located in Vancouver, Washington, a few miles east of the downtown location that housed the company for the last four years. “Absci has been an incredibly positive force in the Vancouver community since establishing its headquarters here in 2016 I have followed Absci’s progress as it expanded within and has now outgrown that initial Vancouver facility. Absci is not only attracting investment and top talent to Washington, it is continuously innovating, creating exciting new possibilities for the future of medicine. I look forward to cutting the ribbon on Absci’s new campus early next month, and to continuing to support the development of our biotechnology ecosystem here in Washington. Washington Governor Jay Inslee The new Absci facility was concepted and constructed in a close collaboration between the company, Portland design firm Bora Architecture & Interiors, and local contractor Bremik Construction. Covering over 85,000 square feet of laboratory, office, and meeting spaces, it features regionally sourced, renewable, and natural building materials, custom finishes, and a vibrant aesthetic. The scalable laboratory space was designed to maximize flow, increase capacity, and readily reconfigure as needed. In addition to tripling capacity for program execution, the incorporation of in-house tissue culture capabilities, high throughput analytical instrumentation, advanced liquid handling and automation, and a dedicated clean air fermentation facility, in conjunction with a state-of-the-art offsite computational cluster, facilitate the expanded scope of Absci’s research and development activities. Additionally, integrated technologies for high volume data capture across Absci’s workflow generate the input for ongoing training of Absci’s Denovium EngineTM deep learning AI models for drug discovery and cell line design. “It’s inspiring to come to work each day in this exceptional building,” said Sean McClain, founder and CEO of Absci. “We designed the light-filled space around collaboration and the pursuit of scientific excellence, and we are thrilled with the pride our Unlimiters feel inhabiting this new campus. We strive every day to bring new insights to challenging problems, and this collaborative setting really encourages all of us to step beyond the impossible to create new possibilities for patients.” “When I visited Absci’s campus, I was impressed by the quality and productivity that imbues the space,” commented Bharat Dixit of ClearB Therapeutics. “The facility is designed with a modern look, yet with practical aspects in mind -- the futuristic gowning rooms, the bright, open lab spaces with lots of natural light and intuitive flow, as well as state-of-the-art robotic equipment, to name a few. And the friendly town hall full of people sharing ideas seems to be a sign of big success ahead.” About Absci Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including Bionic Proteins™ containing nonstandard amino acids, and other novel drug designs that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com. Availability of Other Information about Absci Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites. The information that we post on these websites could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website, or any other website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Absci Forward-Looking Statements Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “may,” "pursues," “anticipates,” “plans,” “believes,” “forecast,” “estimates,” “expects,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding drug development efforts, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to drug development efforts; along with those risks set forth in our Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on September 7, 2021, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

Read More

RESEARCH

PostEra announces $260M multi-target strategic AI Lab collaboration with Pfizer

PostEra | January 12, 2022

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced the expansion of the company's existing strategic collaboration with Pfizer. The expanded multi-target research program will establish an AI Lab where PostEra and Pfizer jointly advance multiple drug discovery programs with an initial focus in oncology and COVID-19 antiviral therapeutics. The AI Lab will leverage novel machine learning for medicinal chemistry built upon Pfizer's data, and PostEra's pioneering innovations in generative chemistry and synthesis-aware design. PostEra will receive an upfront payment of $13M and is eligible to receive additional milestone payments totalling up to $248M should all milestones be achieved, in addition to tiered royalties on any approved products arising out of the collaboration. The AI Lab will tightly integrate drug discovery with technology development to ensure a continuous feedback loop that refines both the process and predictions from the platform. The vision of the AI Lab is to combine Pfizer's expertise and data with PostEra's technology to advance these drug discovery programs, while also producing an integrated state-of-the-art platform to be deployed across Pfizer's in-house, preclinical drug discovery efforts. "We think the best way to build leading technology is to have its development tightly integrated with live drug discovery programs", said Dr. Alpha Lee, Chief Scientific Officer of PostEra. "We're pleased that we are expanding the existing collaboration to do exactly this and to reap the AI advantage in improving preclinical drug discovery," Aaron Morris, CEO of PostEra "At Pfizer, we believe digital technologies, including artificial intelligence and machine learning, hold great potential to aid the discovery of novel approaches to prevent, cure, and treat disease for patients in need," said Charlotte Allerton, Head of Medicine Design, Pfizer. "We're excited to extend our collaboration with PostEra to further build on our current capabilities." The company today also announced its $24M Series A financing. The new funding will enable PostEra to further expand its partnered drug discovery programs, initiate internal drug discovery programs, as well as further develop its AI-first medicinal chemistry platform. About PostEra PostEra was founded in 2019 and its technology is built on pioneering academic research done by its founding scientists. PostEra's technology addresses some of the key challenges in drug discovery R&D by integrating molecular design with chemical synthesis. PostEra advances small molecule programs through partnerships with biopharma, working on its own internal pipeline, and also offering some of its synthesis technology via its Manifold web platform. PostEra also launched and now helps lead the world's largest open-science drug discovery effort; COVID Moonshot.

Read More

INDUSTRIAL IMPACT

Novo Holdings Leads US$21M Series A Financing in BIOMILQ

Novo Holdings | October 21, 2021

BIOMILQ is developing a novel infant feeding option, derived from human mammary cells, to better meet infants' nutritional needs and with a lower carbon footprint than traditional bovine-based infant formula. Earlier this year, BIOMILQ announced it had successfully produced a milk product with many of the same macronutrients that are known to be abundantly present in breastmilk in its lab based in Research Triangle Park in North Carolina, US. In the US, it is estimated that 75%1 of women are unable to exclusively breastfeed for the six months after birth as recommended by the American Academy of Pediatrics and the World Health Organization. Breastfeeding can be difficult due to latching issues, birth complications, discomfort or pain, exhaustion, inadequate milk supply, amongst other reasons. Alternative supplements, such as bovine-based infant formula, can lack the nutritional and bioactive composition found in breast milk. BIOMILQ's technology and solutions can be transformative in the field of infant nutrition, a market with a significant need for innovation. "Our mission is to make a growing and positive impact on health, science and society. We are delighted to support BIOMILQ through its journey pioneering mammary biotechnology. Its products have the potential to disrupt the infant supplemental feeding industry. We aim to use our scientific knowledge, operational expertise and global network to further strengthen the Company's ability to improve lives. Kartik Dharmadhikari, Partner at Novo Groand BIOMILQ Board Director Michelle Egger, Chief Executive Officer and Co Founder of BIOMILQ, added: "We are very pleased to have such experienced investors in our Series A financing. Novo Holdings, as a leading international life science investor, lends significant market experience and technical knowhow to BIOMILQ's mission to nourish healthier infants, empower parents through choice, and contribute to a healthier planet. The investor syndicate was led by Novo Holdings, with participation from Breakthrough Energy Ventures, Blue Horizon, Spero Ventures, Digitalis Ventures, Green Generation Fund and Gaingels. About Novo Holdings A/S Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets. Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information. About BIOMILQ BIOMILQ's mission is to close the nutritional gap between infant feeding options. In June 2021, BIOMILQ announced its capability of producing a milk product, derived from human mammary cells, that has macronutrient profiles that closely match the expected types and proportions of proteins, complex carbohydrates, fatty acids and other bioactive lipids that are known to be abundantly present in breastmilk. 1 "Breastfeeding Among U.S. Children Born 2011–2018, CDC National Immunization Survey." Centers for Disease Control

Read More